A phase II study of lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 3, 2009, Pages 274-279

  Hanrahan, Emer O ^a   Kies, Merrill S ^a   Glisson, Bonnie S ^a   Khuri, Fadlo R ^b   Feng, Lei ^a   Tran, Hai T ^a   Ginsberg, Lawrence E ^a   Truong, Mylene T ^a   Hong, Waun K ^a   Kim, Edward S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Farnesyl transferase inhibitor; Head and neck squamous cell carcinoma; Lonafarnib; Phase II trial

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEFITINIB; GEMCITABINE; LONAFARNIB; METHOTREXATE; MPC 6827; NAVELBINE; PACLITAXEL; PC 6827; PEMETREXED; PLATINUM DERIVATIVE; TEMOZOLOMIDE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BODY WEIGHT; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CARCINOMA; HEART MUSCLE ISCHEMIA; HUMAN; HYPERURICEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INDUCED HYPOTENSION; INFECTION; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; SLEEP DISORDER; SPINAL CORD COMPRESSION; SQUAMOUS CELL CARCINOMA; SYNCOPE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; DRUG RESISTANCE, NEOPLASM; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PIPERIDINES; PROGNOSIS; PYRIDINES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 67749135818     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318187dd57     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Winquist E, Oliver T, Gilbert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck. 2007;29:38-46.
3. Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006;24:2644-2652.
4. Iop A, Cartei G, Isaia A. Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil. Ann Oncol. 1998;9:225-227.
5. Leon X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol). 2005;17:418-424.
6. Genet D, Cupissol D, Calais G, et al. Docetaxel plus 5-fluorouracil in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol. 2004;27:472-476.
7. Argiris A, Goldwasser M, Brockstein BE, et al. Weekly docetaxel (D) and irinotecan (I) in patients (pts) with recurrent or metastatic head and neck cancer (HNC): a phase II trial of the Eastern Cooperative Oncology Group (ECOG). J Clin Oncol, 2005 ASCO Annual Meeting Proceedings. 2005;23(suppl 16):5528.
8. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49: 4682-4689.
9. Hoa M, Davis SL, Ames SJ, et al. Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma Cancer Res. 2002;62:7154-7156.
10. Yarbrough WG, Shores C, Witsell DL, et al. ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope. 1994;104(11 pt 1):1337-1347.
11. Gibbs JB. Ras C-terminal processing enzymes-new drug targets? Cell. 1991;65:1-4.
12. Willumsen BM, Norris K, Papageorge AG, et al. Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. Embo J. 1984;3:2581-2585.
13. Morgillo F, Lee HY. Lonafarnib in cancer therapy. Expert Opin Investig Drugs. 2006;15:709-719.
14. Cox AD, Der CJ. Farnesyl transferase inhibitors and cancer treatment: targeting simply Ras? Biochim Biophys Acta. 1997;1333:F51-F71.
15. Ashar HR, James L, Gray K, et al. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000;275:30451-30457.
16. Kies MS, Clayman GL, El-Naggar AK, et al. Induction therapy with SCH 66336: a farnesyl transferase inhibitor in squamous cell carcinoma (SCC) of the head and neck[abstract]. Proc Am Soc Clin Oncol. 2001;20. Abstract 896.
17. List AF, Deangelo D, O'Brien S, et al. Phase I study of continuous oral administration of lonafarnib (Sarasar) in patients with advanced hematologic malignancies. Blood. 2002;100:789A.
18. Herbert H, Michae CO, William P, et al. Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule[abstract]. Proc Am Soc Clin Oncol. 1999. Abstract 599.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assoc. 1958;53:457-481.
20. Appels NM, Beijnen JH, Schellens JH. Development of farnesyl transferase inhibitors: a review. Oncologist. 2005;10:565-578.
21. Adjei AA, Erlichman C, Davis JN, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000;60:1871-1877.
22. Khuri FR, Glisson BS, Kim ES, et al. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004; 10:2968-2976.
23. Awada A, Eskens FA, Piccart M, et al. Phase I and pharmacological study of the oral farnesyl transferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur J Cancer. 2002;38:2272-2278.
24. Schellens J, de Klerk G, Swart M, et al. Phase I and pharmacologic study with the novel farnesyl transferase inhibitor (FTI) R115777[abstract]. Proc Am Soc Clin Oncol. 2000;19. Abstract 715.
25. Cortes J, Faderl S, Estey E, et al. Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes. J Clin Oncol. 2005;23:2805-2812.
26. Mesa RA. Tipifarnib: farnesyl transferase inhibition at a crossroads. Expert Rev Anticancer Ther. 2006;6:313-319.
27. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25:2171-2177.
28. Tseng JE, Glisson BS, Khuri FR, et al. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer. 2001;92:2364-2373.
29. Tran N, Rose BR, O'Brien CJ. Role of human papillomavirus in the etiology of head and neck cancer. Head Neck 2007;29:64-70.
30. Macdonald JS, McCoy S, Whitehead RP, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG 9924) study. Invest New Drugs. 2005;23:485-487.
31. Heymach JV, Johnson DH, Khuri FR, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Ann Oncol. 2004;15:1187-1193.
32. Adjei AA, Mauer A, Bruzek L, et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2003;21:1760-1766.
33. Winquist E, Moore MJ, Chi KN, et al. A multinomial phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol Oncol. 2005;23:143-149.
34. Sharma S, Kemeny N, Kelsen DP, et al. A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol. 2002;13:1067-1071.
35. Rao S, Cunningham D, de Gramont A, et al. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol. 2004;22:3950-3957.
36. Harousseau JL, Martinelli G, Jedrzejczak WW, et al. A randomized phase 3 study of tipifarnib compared to best supportive care (including hydroxyurea) in the treatment of newly diagnosed acute myeloid leukemia (AML) in patients 70 years or older [abstract]. Blood (ASH Annual Meeting Abstracts). 2007;110. Abstract 439.
37. Whyte DB, Kirschmeier P, Hockenberry TN, et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem. 1997;272:14459-14464.
38. Kim ES, Kies MS, Fossella FV, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer. 2005;104:561-569.
39. Blumenschein G, Ludwig C, Thomas G, et al. A randomized phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/paclitaxel (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC) [abstract]. Proceedings from the 11th World Conference on Lung Cancer, Barcelona, Spain. 2005:Abstract O-082.
40. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol. 2004;22:1430-1438.
41. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 1993;75:175-185.
42. Karp JE, Kaufmann SH, Adjei AA, et al. Current status of clinical trials of farnesyltransferase inhibitors. Curr Opin Oncol. 2001;13:470-476.
43. Gelb MH, Scholten JD, Sebolt-Leopold JS. Protein prenylation: from discovery to prospects for cancer treatment. Curr Opin Chem Biol. 1998;2:40-48.
44. Sebti S, Hamilton AD. Inhibitors of prenyl transferases. Curr Opin Oncol. 1997;9:557-561.
45. Marcus AI, O'Brate AM, Buey RM, et al. Farnesyltransferase inhibitors reverse taxane resistance. Cancer Res. 2006;66:8838-8846.
46. Oh SH, Kim WY, Kim JH, et al. Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12:653-661.
47. Chun KH, Lee HY, Hassan K, et al. Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res. 2003;63:4796-4800.
48. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
49. Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy-Results of a randomized phase III (Extreme) study[abstract]. Proc Am Soc Clin Oncol. 2007. Abstract 6091.